Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Amit Sanyal, MD: A Clinician’s Perspective

May

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?

Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States

Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status

FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer

Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma